Document is current
Any future updates will be listed below
-
Authors
Alten, Rieke
Behar, Claire
Merckaert, Pierre
Afari, Ebenezer
Vannier-Moreau, Virginie
Ohayon, Anael
Connolly, Sean E.
Najm, Aurélie
Juge, Pierre-Antoine
Liu, Gengyuan
Rai, Angshu
Elbez, Yedid
Lozenski, Karissa
- License Information
-
More Information
Article History
Received: 10 July 2024
Accepted: 16 January 2025
First Online: 1 February 2025
Declarations
:
: This study was conducted in accordance with International Society for Pharmacoepidemiology Guidelines for Good Pharmacoepidemiology Practices [20] and applicable regulatory requirements. The ACTION and ASCORE study protocols and patient enrolment materials were approved according to local law in each participating country prior to initiation of each study.
: Not applicable.
: RA: advisory role: AbbVie, Amgen, Biogen, Bristol Myers Squibb, Celltrion, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, Roche. CBe: former consultant: Bristol Myers Squibb.PM, EA: nothing to disclose.VV-M, AO, GL: employee: Bristol Myers Squibb.SEC, KL: employee, shareholder: Bristol Myers Squibb.AN: advisory role: Bristol Myers Squibb, UCB; speaker/honoraria: Bristol Myers Squibb, Galapagos, Roche, UCB; grant/research support: Novartis, AstraZeneca.P-AJ: consultant: Bristol Myers Squibb; speaker/honoraria: AstraZeneca, Boehringer Ingelheim.AR: employee, shareholder: Amgen, Bristol Myers Squibb (at the time of analysis); shareholder: Genmab. Current affiliation: Eli Lilly & Co.YE: consultant: Bristol Myers Squibb.
